Corporate News

Concepta plc (AIM:CPT),  the UK healthcare company and developer of a proprietary product targeted at the mobile health market and with a primary focus on women's fertility, today   announces that  share options over 13,000,000   ordinary shares of the Company (representing approximately 2.65% of the issued ordinary share capital) under the Company's EMI Share Option Scheme at an exercise price of 0.8p per share, being the price of the shares allotted at the General Meeting on 24 April 2020, and have been awarded as follows:

10,000,000 to Penny McCormick

The Options shall time vest as follows:

The options will vest in equal tranches over 3 years from the date of commencement of Mrs McCormick's employment (of 14 November 2019):

2,500,000 to Maddy Kennedy

The Options shall time vest as follows:

The options will vest in full over 1 year from the date of commencement of Mrs Kennedy's employment (of 24 October 2019):

500,000 to Karen Whiting

The Options shall time vest as follows:

The options will vest in equal tranches over 3 years from the date of commencement of Mrs Whiting's employment (of 2 March 2020):

About Concepta PLC ( www.conceptaplc.com )

Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalized mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.

myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus®   is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.

The Company has received CE-mark certification for myLotus®   and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2020.

myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.